Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multi-CAR T Cell Therapy for Acute Myeloid Leukemia
NCT03222674Phase 2Not yet recruiting
- Sponsor
- Shenzhen Geno-Immune Medical Institute
- Start
- Dec 2026
- Primary completion
- Jun 2028
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of Muc1/CLL1/CD33/CD38/CD56/CD123-specific gene-engineered T cells in acute myeloid leukemia (AML), sponsored by Shenzhen Geno-Immune Medical Institute. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
Muc1/CLL1/CD33/CD38/CD56/CD123-specific gene-engineered T cells
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03222674.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03222674.